Trastuzumab Monograph

Introduction/Overview

Trastuzumab is a humanized monoclonal antibody that targets the extracellular domain of the human epidermal growth factor receptor 2 (HER2). It has markedly altered the therapeutic landscape for HER2‑positive breast and gastric cancers. Understanding its pharmacologic profile is essential for clinicians and pharmacists engaged in oncology practice, as its use requires careful monitoring of cardiac function, infusion reactions, and potential drug interactions.

Learning objectives for this chapter include:

• Describe the classification and structural attributes of trastuzumab.
• Explain the pharmacodynamic mechanisms underlying HER2 blockade and downstream signaling inhibition.
• Summarize the pharmacokinetic characteristics, including distribution, elimination, and dose‑adjustment considerations.
• Identify approved therapeutic indications and common off‑label applications.
• Recognize the spectrum of adverse effects, with emphasis on cardiotoxicity and infusion reactions.
• Outline significant drug interactions and special patient populations requiring modified dosing or monitoring.

Classification

Drug Class and Category

Trastuzumab is classified as a monoclonal antibody (mAb), specifically a humanized IgG1 kappa antibody. Within oncology therapeutics, it belongs to the category of targeted biologic agents that interfere with receptor tyrosine kinase signaling. Its mechanism distinguishes it from small‑molecule tyrosine kinase inhibitors, which act intracellularly.

Chemical Classification

Structurally, trastuzumab comprises a variable region (Fab) that recognizes HER2 and a constant region (Fc) that mediates effector functions such as antibody‑dependent cellular cytotoxicity (ADCC). The glycosylation pattern of the Fc domain contributes to its stability and interaction with Fcγ receptors on immune effector cells.

Mechanism of Action

Pharmacodynamics

Binding of trastuzumab to the extracellular domain IV of HER2 sterically hinders receptor dimerization and subsequent autophosphorylation. The blockade prevents activation of downstream signaling cascades, notably the PI3K/AKT and MAPK pathways, which are critical for cell proliferation and survival. Consequently, HER2‑positive tumor cells undergo growth arrest and apoptosis.

Receptor Interactions

Trastuzumab preferentially binds to the A subdomain of HER2, which is distinct from the ligand‑binding domains of other HER family receptors. This specificity reduces cross‑reactivity and allows for selective inhibition of HER2‑mediated signaling. Additionally, trastuzumab promotes receptor internalization and degradation, further diminishing HER2 signaling capacity.

Molecular/Cellular Mechanisms

Beyond direct inhibition, trastuzumab engages immune effector mechanisms. Binding of the Fc region to FcγRIIIa on natural killer (NK) cells triggers ADCC, leading to targeted tumor cell lysis. Furthermore, trastuzumab enhances the presentation of tumor antigens, potentially fostering a broader anti‑tumor immune response. These combined actions magnify its therapeutic efficacy.

Pharmacokinetics

Absorption

Trastuzumab is administered intravenously; thus, bioavailability is effectively 100 %. Intravenous infusion allows for rapid delivery of the therapeutic concentration and circumvents the limitations of parenteral absorption seen with subcutaneous or oral agents.

Distribution

After administration, trastuzumab distributes primarily within the vascular and interstitial compartments. Its large molecular size limits penetration into highly vascularized tissues but permits adequate access to tumor sites via enhanced permeability and retention (EPR) effects. The volume of distribution approximates the plasma volume, with a C_max of 20–30 µg/mL following a 4‑hour infusion.

Metabolism

Monoclonal antibodies are primarily degraded by proteolytic catabolism into amino acids and peptides. Trastuzumab undergoes lysosomal degradation within cells, with minimal involvement of hepatic cytochrome P450 enzymes. Consequently, drug–drug interactions mediated by CYP pathways are unlikely.

Excretion

Renal excretion of intact trastuzumab is negligible, as the molecule is too large to be filtered by the glomerulus. Clearance occurs through proteolytic catabolism in the reticuloendothelial system and within tumor tissues. The apparent clearance (CL) is approximately 0.4 mL/h/kg, translating to a terminal half‑life (t_1/2) of 20–25 days.

Half-Life and Dosing Considerations

Given the extended t_1/2, trastuzumab is typically dosed at an initial loading dose of 4 mg/kg, followed by 2 mg/kg weekly or every‑three‑week schedules, depending on the clinical protocol. Dose adjustments are generally not required for renal impairment, but caution is advised in severe hepatic dysfunction due to potential alterations in protein binding and catabolism.

Therapeutic Uses/Clinical Applications

Approved Indications

• Neoadjuvant or adjuvant therapy for HER2‑positive early‑stage breast cancer.
• Metastatic HER2‑positive breast cancer in combination with chemotherapy (e.g., capecitabine, docetaxel).
• Trastuzumab‑based therapy for HER2‑positive gastric or gastroesophageal junction adenocarcinoma.
• HER2‑positive metastatic colorectal cancer in selected clinical trial settings.

Off-Label Uses

In clinical practice, trastuzumab may be employed in combination with other targeted agents (e.g., pertuzumab) or in palliative settings for HER2‑positive tumors beyond breast and gastric cancers. These off‑label applications are guided by evidence from phase II studies and clinical judgment.

Adverse Effects

Common Side Effects

• Infusion‑related reactions (fever, chills, hypotension) occurring primarily during the first infusion.
• Cardiovascular complications, notably left ventricular ejection fraction (LVEF) reduction and congestive heart failure.
• Gastrointestinal disturbances such as nausea, vomiting, and diarrhea.
• Hematologic effects, including transient neutropenia and anemia.

Serious or Rare Adverse Reactions

• Severe cardiomyopathy, especially when combined with anthracyclines.
• Allergic reactions ranging from mild urticaria to anaphylaxis.
• Infusion‑related hemolysis in patients with pre‑existing hemolytic disorders.
• Rare reports of interstitial lung disease and pulmonary fibrosis.

Black Box Warnings

Trastuzumab carries a black box warning for cardiotoxicity. Regular monitoring of LVEF via echocardiography or MUGA scans is required before each cycle, particularly in patients receiving concurrent cardiotoxic agents. Discontinuation of therapy is advised if LVEF falls ≥10 % from baseline or drops below 50 %.

Drug Interactions

Major Drug-Drug Interactions

• Anthracyclines (e.g., doxorubicin) may synergistically increase cardiotoxic risk; co‑administration necessitates intensified cardiac surveillance.
• Other HER2‑targeted therapies (pertuzumab, lapatinib) may enhance efficacy but also raise the possibility of overlapping toxicities.
• Agents that impair cardiac function (e.g., beta‑blockers, ACE inhibitors) are not contraindicated but require careful baseline cardiac assessment.
• Concomitant use with immunosuppressants (e.g., steroids) may blunt ADCC activity, potentially reducing therapeutic effectiveness.

Contraindications

Absolute contraindication includes active hypersensitivity to trastuzumab or any of its excipients. Relative contraindication applies to patients with severe, uncontrolled cardiac disease or uncontrolled infection.

Special Considerations

Use in Pregnancy/Lactation

Trastuzumab is classified as pregnancy category B, but animal studies have demonstrated fetal cardiac effects. Therefore, use during pregnancy is generally discouraged unless benefits outweigh potential risks. Lactation is contraindicated due to the likelihood of secretion into breast milk and potential cardiac effects on the infant.

Pediatric/Geriatric Considerations

Limited data exist for pediatric patients; trastuzumab is reserved for clinical trials or compassionate use in pediatric HER2‑positive tumors. In geriatric patients, immune senescence may affect ADCC efficacy. Dose adjustments are not routinely required, but vigilant cardiac monitoring is advised.

Renal/Hepatic Impairment

Renal impairment has minimal impact on trastuzumab clearance; no dosage adjustment is recommended. Hepatic impairment may reduce protein binding and increase catabolism; however, clinical data are sparse. Patients with severe hepatic dysfunction should be monitored closely for unexpected adverse events.

Summary/Key Points

• Trastuzumab is a HER2‑targeted monoclonal antibody, acting through receptor blockade and ADCC.
• Its pharmacokinetics are characterized by a long half‑life (~23 days) and minimal CYP involvement.
• Cardiotoxicity remains the most clinically significant adverse effect; routine LVEF monitoring is mandatory.
• Interaction with anthracyclines heightens cardiac risk; concomitant use requires intensified surveillance.
• Pregnancy and lactation are contraindicated; use in pediatric patients is limited to clinical trials.
• Therapeutic efficacy is maximized when trastuzumab is integrated into multidisciplinary regimens for HER2‑positive malignancies.

Clinical pearls include the importance of pre‑infusion assessment for infusion reactions, the utility of echocardiography for early detection of LVEF decline, and the recognition that ADCC potency may be modulated by concurrent immunosuppressive therapy. Mastery of these details is essential for safe and effective trastuzumab administration in oncology practice.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.